Q3 2020 13F Holders as of 9/30/2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
69.8M
-
Number of holders
-
50
-
Total 13F shares, excl. options
-
16.4M
-
Shares change
-
+16.4M
-
Total reported value, excl. options
-
$527M
-
Value change
-
+$527M
-
Number of buys
-
50
-
Price
-
$32.31
Significant Holders of Kymera Therapeutics, Inc. - Common Stock (KYMR) as of Q3 2020
50 filings reported holding KYMR - Kymera Therapeutics, Inc. - Common Stock as of Q3 2020.
Kymera Therapeutics, Inc. - Common Stock (KYMR) has 50 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 16.4M shares
of 69.8M outstanding shares and own 23.45% of the company stock.
Largest 10 shareholders include Redmile Group, LLC (2.73M shares), BVF INC/IL (2.63M shares), FMR LLC (2.26M shares), BAKER BROS. ADVISORS LP (1.96M shares), WELLINGTON MANAGEMENT GROUP LLP (1.76M shares), BlackRock Inc. (767K shares), Bain Capital Life Sciences Investors, LLC (730K shares), Rock Springs Capital Management LP (710K shares), Logos Global Management LP (301K shares), and PRICE T ROWE ASSOCIATES INC /MD/ (295K shares).
This table shows the top 50 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.